Potential effect of HIV type 1 antiretroviral and herpes simplex virus type 2 antiviral therapy on transmission and acquisition of HIV type 1 infection

Journal of Infectious Diseases

Volumn 191, Issue SUPPL. 1, 2005, Pages

  Celum, Connie L ^a   Robinson, Noah J ^c   Cohen, Myron S ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIRETROVIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

ARTICLE; CLINICAL TRIAL; DISEASE PREDISPOSITION; DRUG EFFECT; DRUG SAFETY; GENITAL ULCER; HERPES SIMPLEX VIRUS 2; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; PRIORITY JOURNAL; SYSTEMATIC REVIEW; T LYMPHOCYTE; VERTICAL TRANSMISSION; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; ANTIVIRAL AGENTS; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HIV INFECTIONS; HIV-1; HUMANS; MALE;

EID: 12444276692     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/425272     Document Type: Article

References (59)

1. Royce RA, Sena A, Cates W Jr, Cohen MS. Sexual transmission of HIV. N Engl J Med 1997; 336:1072-8.
2. Greene WC, Peterlin BM. Charting HIV's remarkable voyage through the cell: 000basic science as a passport to future therapy. Nat Med 2002; 8:673-80.
3. Geijtenbeek TB, van Kooyk Y. DC-SIGN: a novel HIV receptor on DCs that mediates HIV-1 transmission. Curr Top Microbiol Immunol 2003; 276:31-54.
4. Steinman RM, Granelli-Piperno A, Pope M, et al. The interaction of immunodeficiency viruses with dendritic cells. Curr Top Microbiol Immunol 2003; 276:1-30.
5. Ketas TJ, Klasse PJ, Spenlehauer C, et al. Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types. AIDS Res Hum Retroviruses 2003; 19:177-86.
6. Overbaugh J, Kreiss J, Poss M, et al. Studies of human immunodeficiency virus type 1 mucosal viral shedding and transmission in Kenya. J Infect Dis 1999; 179:S401-4.
7. O'Brien TR, Winkler C, Dean M, et al. HIV-1 infection in a man homozygous for CCR5 Δ32 [research letter]. Lancet 1997; 349:1219.
8. Zagury D, Lachgar A, Chams V, et al. C-C chemokines, pivotal in protection against HIV type 1 infection. Proc Natl Acad Sci USA 1998; 95:3857-61.
9. Chakraborty H, Sen PK, Helms RW, et al. Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. AIDS 2001; 15:621-7.
10. Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med 1999; 341:394-402.
11. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921-9.
12. Colfax GN, Buchbinder SP, Cornelisse PGA, Vittinghoff E, Mayer KH, Celum CL. Sexual risk behaviors and implications for secondary HIV transmission during and after HIV seroconversion. AIDS 2002; 16:1529-35.
13. + index partner, in discordant couples, Rakai, Uganda [abstract 40]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2003:71.
14. Pilcher CD, Price MA, Hoffman IF, et al. Frequent detection of acute primary HIV infection in men in Malawi. AIDS 2004; 18:517-24.
15. Cohen MS, Hoffman IF, Royce RA, et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group. Lancet 1997; 349:1868-73.
16. Ping LH, Cohen MS, Hoffman I, et al. Effects of genital tract inflammation on human immunodeficiency virus type 1 V3 populations in blood and semen. J Virol 2000; 74:8946-52.
17. Zuckerman RA, Whittington WLH, Celum CL, et al. Factors associated with oropharyngeal human immunodeficiency virus shedding. J Infect Dis 2003; 188:142-5.
18. Geijtenbeek TBH, Kwon DS, Torensma R, et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000; 100:587-97.
19. Patterson BK, Landay A, Siegel JN, et al. Susceptibility to human immunodeficiency virus-1 infection of human foreskin and cervical tissue grown in explant culture. Am J Pathol 2002; 161:867-73.
20. Taha TE, Hoover DR, Dallabetta GA, et al. Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV. AIDS 1998; 12:1699-706.
21. Hosseinipour M, Cohen MS, Vernazza PL, Kashuba AD. Can antiretroviral therapy be used to prevent sexual transmission of human immunodeficiency virus type 1? Clin Infect Dis 2002; 34:1391-5.
22. Cohen MS, Hosseinipour M, Kashuba AD, Butera S. Use of antiretroviral drugs to prevent sexual transmission of HIV. In: Remington JS, Swartz MN, eds. Current clinical topics in infectious diseases. Vol 22. Cambridge, MA: Blackwell Science, 2002:214-51.
23. Tsai CC, Emau P, Follis KE, et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol 1998; 72:4265-73.
24. Roland ME, Martin JN, Grant RM, et al. Postexposure prophylaxis for human immunodeficiency virus infection after sexual or injection drug use exposure: identification and characterization of the source of exposure. J Infect Dis 2001; 184:1608-12.
25. Schechter M, Lago RF, Ismerio R, Mendelsohn AB, Harrison LH. Acceptability, behavioral impact, and possible efficacy of post-sexual-exposure chemoprophylaxis (PEP) for HIV [abstract 15]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002:58.
26. Min SS, Miller WC, Leone PA. A questionnaire study to determine emergency department policy for HIV/STD post-exposure prophylaxis of sexual assault victims in the State of North Carolina [abstract TuPeF5381]. In: Program and abstracts of the 14th International AIDS Conference (Barcelona). Stockholm: International AIDS Society, 2002:612.
27. Vernazza PL. Genital shedding of HIV-1 despite successful antiretroviral therapy [commentary]. Lancet 2001; 358:1564.
28. Kashuba AD, Dyer JR, Kramer LM, Raasch RH, Eron JJ, Cohen MS. Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1999; 43:1817-26.
29. Leigh Brown AJ, Frost SD, Mathews WC, et al. Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis 2003; 187:683-6.
30. Rottingen JA, Cameron DW, Garnett GP. A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known? Sex Transm Dis 2001; 28:579-97.
31. Mertz KJ, Trees D, Levine WC, et al. Etiology of genital ulcers and prevalence of human immunodeficiency virus coinfection in 10 US cities. The Genital Ulcer Disease Surveillance Group. J Infect Dis 1998; 178:1795-8.
32. World Health Organization. Genital ulcer diseases in Africa: epidemiological trends. In: Herpes simplex virus type 2: programmatic and research priorities in developing countries. London: World Health Organization, 2001:13-4.
33. Ballard RC. Genital ulcer adenopathy syndrome. In: Holmes KK, Sparling PF, Mardh P-A, et al., eds. Sexually transmitted diseases. 3rd ed. New York: McGraw-Hill, 1999:887-92.
34. Ballard R, Corey L, Celum CL. HSV and HIV: what is the link? In: Program and abstracts of the Global Herpes Diagnostic Summit (Seattle). Research Triangle Park, NC: American Social Health Association, 2001:33-8.
35. Latif AS, Katzenstein DA, Bassett MT, Houston S, Emmanuel JC, Marowa E. Genital ulcers and transmission of HIV among couples in Zimbabwe. AIDS 1989; 3:519-23.
36. Beyrer C, Jitwatcharanan K, Natpratan C, et al. Molecular methods for the diagnosis of genital ulcer disease in a sexually transmitted disease clinic population in northern Thailand: predominance of herpes simplex virus infection. J Infect Dis 1998; 178:243-6.
37. Bogaerts J, Ricart CA, Van Dyck E, Piot P. The etiology of genital ulceration in Rwanda. Sex Transm Dis 1989; 16:123-6.
38. Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 2002; 185:45-52.
39. Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-discordant couples in Rakai, Uganda. Lancet 2001; 357:1149-53.
40. Grosskurth H, Gray RH, Hayes R, Mabey D, Wawer MJ. Control of sexually transmitted diseases for HIV-1 prevention: understanding the implications of the Mwanza and Rakai trials. Lancet 2000; 355:1981-7.
41. Serwadda D, Gray RH, Sewankambo NK, et al. Human immunodeficiency virus acquisition associated with genital ulcer disease and herpes simplex virus type 2 infection: a nested case-control study in Rakai, Uganda. J Infect Dis 2003; 188:1492-7.
42. Wald A, Zeh JE, Selke SA, Ashley RL, Corey L. Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med 1995; 333:770-5.
43. Smith JS, Robinson NJ. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J Infect Dis 2002; 186(Suppl 1):S3-28.
44. Mbopi-Keou FX, Robinson NJ, Mayaud P, Belec L, Brown DW. Herpes simplex virus type 2 and heterosexual spread of human immunodeficiency virus infection in developing countries: hypotheses and research priorities. Clin Microbiol Infect 2003; 9:161-71.
45. Schacker TW, Ryncarz AJ, Goddard J, Diem K, Shaughnessy M, Corey L. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA 1998; 280:61-6.
46. Gadkari DA, Quinn TC, Gangakhedkar RR, et al. HIV-1 DNA shedding in genital ulcers and its associated risk factors in Pune, India. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18:277-81.
47. Schacker TW, Hu HL, Koelle DM, et al. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons: a double-blind, placebo-controlled trial. Ann Intern Med 1998; 128:21-8.
48. Mbopi-Keou FX, Gresenguet G, Mayaud P, et al. Genital herpes simplex virus type 2 shedding is increased in HIV-infected women in Africa. AIDS 1999; 13:536-7.
49. Mbopi-Keou F-X, Gresenguet G, Mayaud P, et al. Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in African women: opportunities for intervention. J Infect Dis 2000; 182:1090-6.
50. McClelland RS, Wang CC, Overbaugh J, et al. Association between cervical shedding of herpes simplex virus and HIV-1. AIDS 2002; 16:2425-30.
51. Schacker TW, Zeh JE, Hu HL, Hill E, Corey L. Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men. J Infect Dis 1998; 178:1616-22.
52. Augenbraun MH, Feldman J, Chirgwin K, et al. Increased genital shedding of herpes simplex virus type 2 in HIV-seropositive women. Ann Intern Med 1995; 123:845-7.
53. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004; 350:11-20.
54. Gershengorn HB, Darby G, Blower SM. Predicting the emergence of drug-resistant HSV-2: new predictions. BMC Infect Dis 2003; 3:1-5.
55. Blower SM, Porco TC, Darby G. Predicting and preventing the emergence of antiviral drug resistance in HSV-2. Nat Med 1998; 4:673-8.
56. Mertz GJ, Critchlow CW, Benedetti J, et al. Double-blind placebo-controlled trial of oral acyclovir in first-episode genital herpes simplex virus infection. JAMA 1984; 252:1147-51.
57. Blower SM, Gershengorn HB, Grant RM. A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science 2000; 287:650-4.
58. Dukers NH, Goudsmit J, de Wit JB, Prins M, Weverling GJ, Coutinho RA. Sexual risk behaviour relates to the virological and immunological improvements during highly active antiretroviral therapy in HIV-1 HIVA infection. AIDS 2001; 15:369-78.
59. Katz MH, Schwarcz SK, Kellogg TA, et al. Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco. Am J Public Health 2002; 92:388-94.